| 7.43 -0.08 (-1.07%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.63 | 1-year : | 12.28 |
| Resists | First : | 9.1 | Second : | 10.52 |
| Pivot price | 7.36  |
|||
| Supports | First : | 6.82 | Second : | 5.67 |
| MAs | MA(5) : | 7.38 |
MA(20) : | 7.84 |
| MA(100) : | 10.31 |
MA(250) : | 8.19  |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 29.8 |
D(3) : | 21.4 |
| RSI | RSI(14): 37.1 |
|||
| 52-week | High : | 14.68 | Low : | 3.39 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NAGE ] has closed below upper band by 40.6%. Bollinger Bands are 75% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.53 - 7.57 | 7.57 - 7.61 |
| Low: | 7.04 - 7.1 | 7.1 - 7.15 |
| Close: | 7.34 - 7.43 | 7.43 - 7.5 |
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
Wed, 22 Oct 2025
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Tue, 21 Oct 2025
Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Business Wire
Fri, 17 Oct 2025
Niagen Bioscience, Inc. (NAGE) Stock Analysis: Unlocking a Potential 116% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Mon, 06 Oct 2025
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth - Business Wire
Mon, 06 Oct 2025
Niagen Bioscience raises 2025 sales outlook on NAD+ market growth - Investing.com
Fri, 03 Oct 2025
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 25% Cheaper Price Remains In Tune With Revenues - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 80 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 34 (%) |
| Held by Institutions | 37.7 (%) |
| Shares Short | 3,750 (K) |
| Shares Short P.Month | 4,340 (K) |
| EPS | 0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.81 |
| Profit Margin | 15.2 % |
| Operating Margin | 10.2 % |
| Return on Assets (ttm) | 14.3 % |
| Return on Equity (ttm) | 37.3 % |
| Qtrly Rev. Growth | 36.7 % |
| Gross Profit (p.s.) | 0.92 |
| Sales Per Share | 1.45 |
| EBITDA (p.s.) | 0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 21 (M) |
| Levered Free Cash Flow | 15 (M) |
| PE Ratio | 33.77 |
| PEG Ratio | 0 |
| Price to Book value | 9.17 |
| Price to Sales | 5.09 |
| Price to Cash Flow | 27.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|